Ethics Approval and Consent to Participate

Ethical approval and consent to participate: The study was approved by the institutional review board of Ärztekammer des Saarlandes, Germany (ethics committee approval number 140/17), and informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the Helsinki Declaration as revised in 2013 and its later amendments.

Consent for Publication

The participants signed consent regarding publishing their data (and/or photographs).

Declaration of Generative AI in Scientific Writing

Authors did not use generative AI in writing.

Competing interest

Florian Rosar, Arne Blickle, Moritz B. Bastian, Tilman Speicher, Andrea Schaefer-Schuler, Caroline Burgard, Stephan Maus, and Samer Ezziddin declare that they have no competing interests.

Clinical Trial Number

NCT04833517, Registry: Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study), registration date: 2016–01-01.